ABSTRACT
COVID-19 is a public health emergency with cases increasing globally. Its clinical manifestations range from asymptomatic and acute respiratory disease to multiple organ dysfunction syndromes and effects of COVID-19 in the long term. Interestingly, regardless of variant, all COVID-19 share impairment of the sense of smell and taste. We would like to report, as far as we know, the first comprehensive neurophysiological evaluation of the long-term effects of SARS-CoV-2 on the olfactory system with potential-related neurological damage. The case report concerns a military doctor, with a monitored health history, infected in April 2020 by the first wave of the epidemic expansion while on military duty in Codogno (Milan). In this subject, we find the electrophysiological signal in the periphery, while its correlate is absent in the olfactory bulb region than in whole brain recordings. In agreement with this result is the lack of metabolic signs of brain activation under olfactory stimulation. Consequently, quantitative and qualitative diagnoses of anosmia were made by means of olfactometric tests. We strongly suggest a comprehensive series of olfactometric tests from the first sign of COVID-19 and subsequent patient assessments. In conclusion, electrophysiological and metabolic tests of olfactory function have made it possible to study the long-term effects and the establishment of neurological consequences.
Subject(s)
Anosmia/physiopathology , Anosmia/virology , COVID-19/complications , Adult , COVID-19/physiopathology , Electrophysiology/methods , Evoked Potentials/physiology , Humans , Male , Olfactory Bulb/physiopathology , Olfactory Nerve/physiopathology , SARS-CoV-2 , Sensory Thresholds/physiology , Post-Acute COVID-19 SyndromeABSTRACT
OBJECTIVE: To investigate the changes of olfactory function and odor-induced brain activation in patients with systemic lupus erythematosus (SLE) at early stages compared with healthy controls. MATERIALS AND METHODS: Olfactory function and odor-induced brain activation in 12 SLE patients at early stages and 12 age, gender and education matched healthy controls were evaluated using olfactory behavior test and odor-induced task-functional magnetic resonance imaging (task-fMRI). RESULTS: No significant differences in olfactory behavior scores (including olfactory threshold, olfactory identification, and olfactory memory) were found in the patients with SLE at early stages compared with the healthy controls, while significantly decreased odor-induced activations in olfactory-related brain regions were observed in the patients. In the SLE group, the patients with better performance in the olfactory threshold test had significantly lower levels of anti-dsDNA antibody. CONCLUSION: The current study demonstrated that significant alterations in odor-induced brain activations occurred prior to measurable olfactory decline in SLE at early stages, which provided a new method for early diagnosis of olfactory dysfunction in SLE.
Subject(s)
Brain/physiopathology , Lupus Erythematosus, Systemic/physiopathology , Olfaction Disorders/physiopathology , Olfactory Nerve/physiopathology , Adult , Antibodies, Antinuclear/blood , Brain/diagnostic imaging , Brain Mapping/methods , Case-Control Studies , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/physiopathology , Early Diagnosis , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Magnetic Resonance Imaging/methods , Neural Conduction/physiology , Neuropsychological Tests/standards , Olfaction Disorders/etiology , Prospective Studies , Sensory Thresholds/physiology , Severity of Illness IndexABSTRACT
Sensory processing deficits are increasingly recognized as core symptoms of autism spectrum disorders (ASDs). However the molecular and circuit mechanisms that lead to sensory deficits are unknown. We show that two molecularly disparate mouse models of autism display similar deficits in sensory-evoked responses in the mouse olfactory system. We find that both Cntnap2- and Shank3-deficient mice of both sexes exhibit reduced response amplitude and trial-to-trial reliability during repeated odor presentation. Mechanistically, we show that both mouse models have weaker and fewer synapses between olfactory sensory nerve (OSN) terminals and olfactory bulb tufted cells and weaker synapses between OSN terminals and inhibitory periglomerular cells. Consequently, deficits in sensory processing provide an excellent candidate phenotype for analysis in ASDs.NEW & NOTEWORTHY The genetics of autism spectrum disorder (ASD) are complex. How the many risk genes generate the similar sets of symptoms that define the disorder is unknown. In particular, little is understood about the functional consequences of these genetic alterations. Sensory processing deficits are important aspects of the ASD diagnosis and may be due to unreliable neural circuits. We show that two mouse models of autism, Cntnap2- and Shank3-deficient mice, display reduced odor-evoked response amplitudes and reliability. These data suggest that altered sensory-evoked responses may constitute a circuit phenotype in ASDs.
Subject(s)
Autism Spectrum Disorder/physiopathology , Olfaction Disorders/physiopathology , Olfactory Bulb/physiopathology , Olfactory Nerve/physiopathology , Olfactory Perception/physiology , Perceptual Disorders/physiopathology , Synaptic Potentials/physiology , Animals , Calcium , Disease Models, Animal , Female , Male , Membrane Proteins/deficiency , Mice , Mice, Knockout , Microfilament Proteins/deficiency , Microscopy, Fluorescence, Multiphoton , Nerve Tissue Proteins/deficiency , Patch-Clamp Techniques , PhenotypeABSTRACT
BACKGROUND: The olfactory nerve was conceptualized in the 4th century BC by Alcmaeon and described anatomically by Winslow in 1733. Cranial nerves (CNs) were named and numbered by Soemmerring in 1791. Notions still prevail that the olfactory (CN1) is not a "true" cranial nerve. METHODS: To confirm our impression that the olfactory nerve is infrequently tested by North American pediatric neurologists, a survey was distributed to members of national pediatric neurology societies in Mexico, Canada, and the United States. A total of 233 responses were received to 6 multiple-choice questions regarding practice patterns examining CN1 in neonates and children and in metabolic, endocrine, and genetic disorders and cerebral malformations. Two of the questions addressed familiarity with neonatal olfactory reflexes and asked whether the olfactory is a "true" cranial nerve. RESULTS: Only 16% to 24% of North American pediatric neurologists examine CN1 in neonates, even in conditions in which olfaction may be impaired. About 40% of respondents were aware of olfactory reflexes. A minority 15% did not consider CN1 as a "true" cranial nerve. CONCLUSIONS: Olfactory evaluation in neonates is simple, rapid, and inexpensive. It tests parts of the brain not otherwise examined. It may assist diagnosis in cerebral malformations; metabolic, endocrine, and hypoxic encephalopathies; and some genetic diseases, including chromosomopathies. CN1 is neuroanatomically unique and fulfills criteria of a true sensory cranial nerve. We recommend that olfaction be routinely or selectively included during neurologic examination of neonates and children.
Subject(s)
Neurologic Examination , Olfactory Nerve/physiopathology , Smell/physiology , Child , Female , Humans , Male , Neurologists , Neurology , Surveys and QuestionnairesABSTRACT
Evoked potentials are time-locked electrophysiologic potentials recorded in response to standardized stimuli using scalp electrodes. These responses provide good temporal resolution and have been used in various clinical and intraoperative settings. Olfactory evoked potentials (OEPs) may be used as an adjunct tool in identifying patients of Parkinson disease and Alzheimer dementia. In clinical practice, visual evoked potentials (VEPs) are particularly useful in identifying subclinical cases of optic neuritis and in treatment surveillance. In recent times, pattern electroretinograms and photopic negative response have been gaining attention in identifying glaucoma suspects. During surgical manipulation, there is a risk of damage to optic or olfactory nerve. Intraoperative neurophysiologic monitoring can provide information regarding the integrity of olfactory or visual pathway. OEPs and VEPs, however, show high degree of variability and are not reliable tools because the responses are extremely susceptible to volatile anesthetic agents. Newer techniques that could possibly circumvent these drawbacks have been developed but are not used extensively. In this article, we briefly review the available techniques to obtain OEPs and VEPs, diagnostic applications, the utility of intraoperative monitoring, the limitations of the current techniques, and the future directions for research.
Subject(s)
Evoked Potentials/physiology , Monitoring, Intraoperative/methods , Olfactory Nerve/physiopathology , Optic Nerve/physiopathology , Humans , Olfactory Pathways/pathology , Olfactory Pathways/physiopathology , Outpatients , Visual Pathways/pathology , Visual Pathways/physiopathologyABSTRACT
Olfactory dysfunction is broadly associated with neurodevelopmental and neurodegenerative diseases and predicts increased mortality rates in healthy individuals. Conventional measurements of olfactory health assess odor processing pathways within the brain and provide a limited understanding of primary odor detection. Quantification of the olfactory sensory neurons (OSNs), which detect odors within the nasal cavity, would provide insight into the etiology of olfactory dysfunction associated with disease and mortality. Notably, OSNs are continually replenished by adult neurogenesis in mammals, including humans, so OSN measurements are primed to provide specialized insights into neurological disease. Here, we have evaluated a PET radiotracer, [11C]GV1-57, that specifically binds mature OSNs and quantifies the mature OSN population in vivo. [11C]GV1-57 monitored native OSN population dynamics in rodents, detecting OSN generation during postnatal development and aging-associated neurodegeneration. [11C]GV1-57 additionally measured rates of neuron regeneration after acute injury and early-stage OSN deficits in a rodent tauopathy model of neurodegenerative disease. Preliminary assessment in nonhuman primates suggested maintained uptake and saturable binding of [18F]GV1-57 in primate nasal epithelium, supporting its translational potential. Future applications for GV1-57 include monitoring additional diseases or conditions associated with olfactory dysregulation, including cognitive decline, as well as monitoring effects of neuroregenerative or neuroprotective therapeutics.
Subject(s)
Aging , Olfaction Disorders/diagnostic imaging , Olfactory Nerve/diagnostic imaging , Olfactory Pathways/diagnostic imaging , Positron-Emission Tomography/methods , Tauopathies/diagnostic imaging , Animals , Male , Olfaction Disorders/physiopathology , Olfactory Nerve/physiopathology , Olfactory Pathways/physiopathology , Radioactive Tracers , Rats , Rats, Sprague-Dawley , Tauopathies/physiopathologyABSTRACT
Olfactory dysfunction is recognised across an ever broadening spectrum of neuropsychiatric conditions including central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO). In this review, we unravel the striking evidence highlighting how olfactory loss is a common clinical feature in MS and NMO. We provide an overview of the supportive psychophysical, electrophysiological, radiological and pathological data that point to the anatomical substrate of olfactory deficits in these diseases. The pattern of underlying pathology affecting the olfactory system is shown to be complex, involving multiple structures that are affected in different ways throughout the course of the disease. This review is the first to synthesise the expanding body of literature on the topic, provides novel insight into the way in which the olfactory system is affected in CNS demyelinating diseases, and raises intriguing questions about the role of this system in the pathogenesis of these diseases.
Subject(s)
Demyelinating Diseases/diagnosis , Demyelinating Diseases/physiopathology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/physiopathology , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/physiopathology , Olfaction Disorders/diagnosis , Olfaction Disorders/physiopathology , Olfactory Pathways/physiopathology , Smell/physiology , Brain Mapping , Demyelinating Diseases/pathology , Encephalomyelitis, Acute Disseminated/diagnosis , Encephalomyelitis, Acute Disseminated/physiopathology , Evoked Potentials/physiology , Humans , Magnetic Resonance Imaging , Multiple Sclerosis/pathology , Neuromyelitis Optica/pathology , Olfaction Disorders/pathology , Olfactory Bulb/physiopathology , Olfactory Cortex/physiopathology , Olfactory Nerve/physiopathology , Sensory Thresholds/physiologyABSTRACT
OBJECTIVE: To explore the impact and mechanism of electro-acupuncture (EA) on olfactory ensheathing cells (OECs) transplantation of spinal cord injury (SCI) axonal regeneration. METHODS: In the experiment, 72 adult Sprague Dawley male rats weighted (220±20) g underwent contusion and transection method to cause the T9 model of spinal cord injury, were randomly divided into four groups involving model group, EA group,OECs group,and EA+OECs group. 5% fluorescein gold (FG) solution of 0.5 µl was injected into rats' spinal cord at 4 weeks and 8 weeks after SCI, a series of tests were performed including fluorescein gold(FG) retrograde tagging, BBB scores. RESULTS: (1)The BBB scores level among four groups had no differences from the 1st day to the 1st week after the SCI (P>0.05). From the 3rd week after the SCI, the BBB scores level in EA+ OECs group were obviously higher than that of other groups (P<0.05). (2)The result of the fluorescein gold (FG) retrograde tagging showed at 4 weeks and 8 weeks after treatment FG positive nerve fibers were observed in SCI region. In EA+OECs group the number of FG positive nerve fibers was more than other three groups, and the fibers were more regularly arranged than other three groups. CONCLUSION: The combination of electro-acupuncture and OECs transplantation can recover the pathway of nerve conduction and promote nerve fibers regeneration and hind limb function recovery for SCI rat, and can guide the trend of the axonal regeneration.
Subject(s)
Axons/physiology , Electroacupuncture , Nerve Regeneration , Olfactory Nerve/transplantation , Spinal Cord Injuries/therapy , Animals , Cell Transplantation , Combined Modality Therapy , Humans , Male , Olfactory Nerve/physiopathology , Rats , Rats, Sprague-Dawley , Spinal Cord Injuries/physiopathologyABSTRACT
The olfactory system is a fascinating and beguiling sensory system: olfactory sensory neurons detect odors underlying behaviors essential for mate choice, food selection, and escape from predators, among others. These sensory neurons are unique in that they have dendrites contacting the outside world, yet their first synapse lies in the central nervous system. The information entering the central nervous system is used to create odor memories that play a profound role in recognition of individuals, places, and appropriate foods. Here, the structure of the olfactory epithelium is given as an overview to discuss the origin of the olfactory placode, the plasticity of the olfactory sensory neurons, and finally the origins of the gonadotropin-releasing hormone neuroendocrine cells. For the purposes of this review, the development of the peripheral sensory system will be analyzed, incorporating recently published studies highlighting the potential novelties in development mechanisms. Specifically, an emerging model where the olfactory epithelium and olfactory bulb develop simultaneously from a continuous neurectoderm patterned at the end of gastrulation, and the multiple origins of the gonadotropin-releasing hormone neuroendocrine cells associated with the olfactory sensory system development will be presented. Advances in the understanding of the basic mechanisms underlying olfactory sensory system development allows for a more thorough understanding of the potential causes of human disease.
Subject(s)
Nerve Regeneration/physiology , Neurodegenerative Diseases/pathology , Olfactory Nerve/physiopathology , Olfactory Pathways/embryology , Olfactory Receptor Neurons/cytology , Smell/physiology , Animals , Humans , Neurodegenerative Diseases/etiology , Olfactory Pathways/cytologyABSTRACT
Hyposmia is often undiagnosed despite the known negative effect on taste, appetite and life quality. However, a new focus on the first cranial nerve has emerged as a consequence of a discovered connection between neurodegenerative disorders and hyposmia. In Parkinson's disease and Alzheimer's disease hyposmia is not only one of the earliest clinical presentations, the degree of hyposmia also correlates with the later progression of these two conditions. Hyposmia should not be ignored nor accepted; instead it should be integrated in any neurological examination, especially in elderly patients.
Subject(s)
Olfaction Disorders , Aged , Alzheimer Disease/diagnosis , Alzheimer Disease/physiopathology , Early Diagnosis , Humans , Olfaction Disorders/diagnosis , Olfaction Disorders/etiology , Olfaction Disorders/physiopathology , Olfactory Nerve/physiopathology , Parkinson Disease/diagnosis , Parkinson Disease/physiopathology , Smell/physiologyABSTRACT
OBJECTIVE: Idiopathic environmental intolerance (IEI) to smells is a prevalent medically unexplained illness. Sufferers attribute severe symptoms to low doses of non-toxic chemicals. Despite the label, IEI is not characterized by acute chemical senses. Theoretical models suggest that sensitized responses in the limbic system of the brain constitute an important mechanism behind the symptoms. The aim was to investigate whether and how brain reactions to low-levels of olfactory and trigeminal stimuli differ in individuals with and without IEI. METHODS: Brain responses to intranasally delivered isoamyl acetate and carbon dioxide were assessed in 25 women with IEI and 26 non-ill controls using functional magnetic resonance imaging. RESULTS: The IEI group had higher blood-oxygenated-level-dependent (BOLD) signal than controls in the thalamus and a number of, mainly, parietal areas, and lower BOLD signal in the superior frontal gyrus. The IEI group did not rate the exposures as more intense than the control group did, and there were no BOLD signal differences between groups in the piriform cortex or olfactory regions of the orbitofrontal cortex. CONCLUSIONS: The IEI reactions were not characterized by hyper-responsiveness in sensory areas. The results can be interpreted as a limbic hyperreactivity and speculatively as an inability to inhibit salient external stimuli.
Subject(s)
Brain/physiopathology , Magnetic Resonance Imaging , Multiple Chemical Sensitivity/diagnosis , Multiple Chemical Sensitivity/physiopathology , Odorants , Olfactory Nerve/physiopathology , Trigeminal Nerve/physiopathology , Adult , Carbon Dioxide , Environmental Illness/diagnosis , Environmental Illness/physiopathology , Female , Humans , Parietal Lobe/physiopathology , Pentanols , Prefrontal Cortex/physiopathology , Thalamus/physiopathologyABSTRACT
Providing expert opinion in the context of smell disorders is often challenging, not only with regard to general aspects of providing an expert opinion but particularly with regard to chemosensory testing. Currently there is no consensus which chemosensory test should be selected and how they should be executed. This positions paper from Committee on Olfaction and Gustation of the German Society of Otorhinolaryngology, Head and Neck Surgery aims to give concrete recommendations for chemosensory testing for providing expert opinion for smell disorders with regard to the selection and execution of these test.
Subject(s)
Expert Testimony/legislation & jurisprudence , Olfaction Disorders/diagnosis , Ageusia/diagnosis , Ageusia/physiopathology , Europe , Evoked Potentials, Somatosensory/physiology , Humans , Olfaction Disorders/physiopathology , Olfactometry/methods , Olfactory Nerve/physiopathology , Predictive Value of Tests , Psychophysics , Reaction Time/physiologyABSTRACT
With an ageing population and increasing prevalence of central-nervous system (CNS) disorders new approaches are required to sustain the development and successful delivery of therapeutics into the brain and CNS. CNS drug delivery is challenging due to the impermeable nature of the brain microvascular endothelial cells that form the blood-brain barrier (BBB) and which prevent the entry of a wide range of therapeutics into the brain. This review examines the role intranasal delivery may play in achieving direct brain delivery, for small molecular weight drugs, macromolecular therapeutics and cell-based therapeutics, by exploitation of the olfactory and trigeminal nerve pathways. This approach is thought to deliver drugs into the brain and CNS through bypassing the BBB. Details of the mechanism of transfer of administrated therapeutics, the pathways that lead to brain deposition, with a specific focus on therapeutic pharmacokinetics, and examples of successful CNS delivery will be explored.
Subject(s)
Blood-Brain Barrier/drug effects , Brain Diseases/drug therapy , Brain/drug effects , Central Nervous System Agents/pharmacokinetics , Drug Delivery Systems , Nasal Mucosa/drug effects , Neurons/drug effects , Administration, Intranasal , Animals , Blood-Brain Barrier/metabolism , Blood-Brain Barrier/physiopathology , Brain/metabolism , Brain Diseases/metabolism , Brain Diseases/physiopathology , Central Nervous System Agents/administration & dosage , Central Nervous System Agents/chemistry , Central Nervous System Agents/therapeutic use , Drug Delivery Systems/trends , Humans , Molecular Weight , Nasal Mucosa/metabolism , Nasal Mucosa/physiopathology , Neurons/metabolism , Olfactory Nerve/drug effects , Olfactory Nerve/metabolism , Olfactory Nerve/physiopathology , Trigeminal Nerve/drug effects , Trigeminal Nerve/metabolism , Trigeminal Nerve/physiopathologyABSTRACT
OBJECTIVE: To investigate the effects of combined acupuncture and eugenol on learning-memory ability and the antioxidation system of the hippocampus in Alzheimer disease (AD) rats. METHODS: Sixty Sprague Dawley rats, weighing (300 +/- 10) g, were randomly divided with 10 rats per group into a normal control group, AD model group, AD with cut olfactory nerve group, Xiu three-needle group, eugenol group, and combined acupuncture and eugenol group. The AD model was established by injection of amyloid beta1-40 (Abeta 1-40). Morris maze tests were conducted for evaluating the learning-memory ability. Content of malondialdehyde (MDA) and activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in the hippocampus were detected. RESULTS: The average escape latency and the mean swimming distance in the normal control group, the Xiu three-needle group, the eugenol group, and the combined acupuncture and eugenol group were significantly shorter than those in the AD model group (all P < 0.01). The combined acupuncture and eugenol group had shorter escape latency and mean swimming distance than those in the Xiu three-needle group and the eugenol group. There were no significant differences between the Xiu three-needle group and the eugenol group and between the AD group and the AD with cut olfactory nerve group (P > 0.05). Compared with the normal control group, the MDA content in the hippocampus significantly increased (P < 0.05) and GSH-Px and SOD activities significantly decreased in the AD model group (P < 0.01). Compared with the AD model group, significantly decreased (P < 0.01) and SOD and GSH-Px activities significantly increased in the Xiu three-needle group, eugenol group, and combined acupuncture and eugenol group (P < 0.05). Compared with the Xiu three-needle group and eugenol group, the MDA content significantly decreased (P < 0.05) and SOD and GSH-Px activities increased (P < 0.05) in the combined acupuncture and eugenol group. There were no significant differences among the three indices between the Xiu three-needle group and the eugenol group and between the AD model group and the AD with cut olfactory nerve group (P > 0.05). CONCLUSION: Both Xiu three-needle and eugenol can increase learning-memory ability, decrease MDA content, and increase SOD and GSH-Px activities in the hippocampus in AD rats. The combination of acupuncture with eugenol has stronger effects, and the effects depend on the olfactory pathway.
Subject(s)
Acupuncture Therapy , Alzheimer Disease/therapy , Eugenol/administration & dosage , Hippocampus/metabolism , Olfactory Nerve/physiopathology , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , Alzheimer Disease/psychology , Animals , Combined Modality Therapy , Female , Hippocampus/drug effects , Humans , Learning/drug effects , Male , Memory/drug effects , Olfactory Nerve/drug effects , Rats , Rats, Sprague-DawleyABSTRACT
IMPORTANCE: A new treatment of neural anosmia. OBJECTIVE: To investigate the effects of basic fibroblast growth factor (bFGF)-gelatin hydrogel on recovery of neural anosmia in mice. DESIGN: Anosmia was induced by intraperitoneal injection of 3-methylindole, 200 mg/kg. One week later, the animals underwent 1 of the following 3 procedures bilaterally: (1) group A: single-shot intranasal drip infusion of phosphate-buffered saline, (2) group B: single-shot intranasal drip infusion of bFGF, and (3) group C: placement of bFGF-gelatin hydrogel in the nasal cavity. The olfactory function of the animal was evaluated by the odor-detection test (ODT) 2 and 4 weeks later. Following the testing, the animal was killed, the thickness of the olfactory epithelium was measured, and the number of olfactory marker protein (OMP)-positive cells was counted. SETTING: Research installation. PARTICIPANTS: Mice. INTERVENTION: The placement of bFGF-gelatin hydrogel in the nasal cavity. MAIN OUTCOMES AND MEASURES: An ODT, thickness of olfactory epithelium, the number of OMP-positive cells RESULTS: The ODT proved that neural anosmia recovered in group C but not in groups A and B. Histologically, olfactory epithelium became thicker and the number of OMP-positive cells increased in group C, while such functional and histologic recovery was poor in groups A and B. These findings suggested that placement of bFGF-gelatin hydrogel in the nasal cavity was an efficient way to facilitate recovery of neural anosmia. CONCLUSIONS AND RELEVANCE: As a gelatin hydrogel degrades slowly in the body, bFGF is gradually released around the site of the lesion; thus, it constantly exerts its effects on neural regeneration.
Subject(s)
Fibroblast Growth Factor 2/administration & dosage , Olfaction Disorders/drug therapy , Smell/physiology , Administration, Topical , Animals , Disease Models, Animal , Female , Fibroblast Growth Factor 2/therapeutic use , Gelatin/administration & dosage , Hydrogel, Polyethylene Glycol Dimethacrylate/administration & dosage , Mice , Mice, Inbred BALB C , Nasal Cavity , Olfaction Disorders/physiopathology , Olfactory Mucosa/drug effects , Olfactory Nerve/drug effects , Olfactory Nerve/physiopathology , Treatment OutcomeABSTRACT
PURPOSE: The aim of this study was to assess whether migration of thallium-201 ((201)Tl) to the olfactory bulb were reduced in patients with olfactory impairments in comparison to healthy volunteers after nasal administration of (201)Tl. PROCEDURES: 10 healthy volunteers and 21 patients enrolled in the study (19 males and 12 females; 26-71 years old). The causes of olfactory dysfunction in the patients were head trauma (nâ=â7), upper respiratory tract infection (nâ=â7), and chronic rhinosinusitis (nâ=â7). (201)TlCl was administered unilaterally to the olfactory cleft, and SPECT-CT was conducted 24 h later. Separate MRI images were merged with the SPECT images. (201)Tl olfactory migration was also correlated with the volume of the olfactory bulb determined from MRI images, as well as with odor recognition thresholds measured by using T&T olfactometry. RESULTS: Nasal (201)Tl migration to the olfactory bulb was significantly lower in the olfactory-impaired patients than in healthy volunteers. The migration of (201)Tl to the olfactory bulb was significantly correlated with odor recognition thresholds obtained with T&T olfactometry and correlated with the volume of the olfactory bulb determined from MRI images when all subjects were included. CONCLUSIONS: Assessment of the (201)Tl migration to the olfactory bulb was the new method for the evaluation of the olfactory nerve connectivity in patients with impaired olfaction.
Subject(s)
Magnetic Resonance Imaging , Olfaction Disorders/diagnostic imaging , Olfaction Disorders/metabolism , Olfactory Nerve/diagnostic imaging , Thallium Radioisotopes/metabolism , Tomography, Emission-Computed, Single-Photon , Administration, Intranasal , Adult , Aged , Biological Transport , Case-Control Studies , Craniocerebral Trauma/complications , Female , Humans , Male , Middle Aged , Olfaction Disorders/etiology , Olfaction Disorders/physiopathology , Olfactory Bulb/diagnostic imaging , Olfactory Bulb/metabolism , Olfactory Bulb/pathology , Olfactory Bulb/physiopathology , Olfactory Nerve/metabolism , Olfactory Nerve/pathology , Olfactory Nerve/physiopathology , Respiratory Tract Infections/complications , Sensory Thresholds , Sinusitis/complications , Thallium Radioisotopes/administration & dosageABSTRACT
OBJECTIVES/HYPOTHESIS: In this study we investigated the effectiveness of vitamin A in postinfectious and posttraumatic smell disorders. A possible effect of vitamin A is likely due to the stimulation of regeneration and repair of the peripheral olfactory system. STUDY DESIGN: Double-blind, randomized, placebo-controlled clinical trial. METHODS: A total of 52 patients (age range, 20-70 years; mean age, 52 years) participated, 26 of whom received placebo (7 male, 19 female) and another 26 verum (8 male, 18 female). A standardized history was obtained in each patient. Olfactory function was measured by means of the Sniffin' Sticks test kit, a validated technique to investigate odor thresholds, odor discrimination, and odor identification. Vitamin A was prescribed at a dose of 10,000 IU per day for 3 months. Follow-up testing was performed on average 5 months after the first investigation. RESULTS: Forty-four percent of all patients reported recovery of their sense of smell; 29% of the participants exhibited significant improvement in measured olfactory function. However, there was no significant difference between the outcome of patients receiving verum or placebo. CONCLUSIONS: The systemic application of vitamin A at a dose of 10,000 IU per day for 3 months does not appear to be useful in the treatment of postinfectious or posttraumatic olfactory loss.
Subject(s)
Nose/injuries , Olfaction Disorders/drug therapy , Olfactory Nerve/physiopathology , Smell/drug effects , Vitamin A/therapeutic use , Administration, Oral , Adult , Aged , Analysis of Variance , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged , Olfaction Disorders/etiology , Olfaction Disorders/physiopathology , Reference Values , Rhinitis/complications , Rhinitis/diagnosis , Severity of Illness Index , Treatment Outcome , Wounds and Injuries/complications , Young AdultABSTRACT
BACKGROUND: Complications of idiopathic intracranial hypertension (IIH) are usually caused by elevated intracranial pressure (ICP). In a similar way as in the optic nerve, elevated ICP could also compromise the olfactory nerve system. On the other side, there is growing evidence that an extensive lymphatic network system around the olfactory nerves could be disturbed in cerebrospinal fluid disorders like IIH. The hypothesis that patients with IIH suffer from hyposmia has been suggested in the past. However, this has not been proven in clinical studies yet. This pilot study investigates whether structural changes of the olfactory nerve system can be detected in patients with IIH. METHODOLOGY/PRINCIPAL FINDINGS: Twenty-three patients with IIH and 23 matched controls were included. Olfactory bulb volume (OBV) and sulcus olfactorius (OS) depth were calculated by magnetic resonance techniques. While mean values of total OBV (128.7±38.4 vs. 130.0±32.6 mm(3), p=0.90) and mean OS depth (8.5±1.2 vs. 8.6±1.1 mm, p=0.91) were similar in both groups, Pearson correlation showed that patients with a shorter medical history IIH revealed a smaller OBV (r=0.53, p<0.01). In untreated symptomatic patients (n=7), the effect was greater (r=0.76, p<0.05). Patients who suffered from IIH for less than one year (n=8), total OBV was significantly smaller than in matched controls (116.6±24.3 vs. 149.3±22.2 mm(3), p=0.01). IIH patients with visual disturbances (n=21) revealed a lower OS depth than patients without (8.3±0.9 vs. 10.8±1.0 mm, p<0.01). CONCLUSIONS/SIGNIFICANCE: The results suggest that morphological changes of the olfactory nerve system could be present in IIH patients at an early stage of disease.